Protalix BioTherapeutics Files 8-K on Security Holder Rights
Ticker: PLX · Form: 8-K · Filed: Dec 31, 2024 · CIK: 1006281
| Field | Detail |
|---|---|
| Company | Protalix Biotherapeutics, Inc. (PLX) |
| Form Type | 8-K |
| Filed Date | Dec 31, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, rights
TL;DR
Protalix 8-K filed: Changes to security holder rights and corporate docs. Review needed.
AI Summary
Protalix BioTherapeutics, Inc. filed an 8-K on December 31, 2024, reporting events that occurred on December 27, 2024. The filing indicates material modifications to the rights of security holders and amendments to its articles of incorporation or bylaws. It also includes financial statements and exhibits.
Why It Matters
This filing signals potential changes affecting Protalix BioTherapeutics' shareholders and corporate structure, requiring investors to review the specific modifications and amendments.
Risk Assessment
Risk Level: medium — Changes to security holder rights and corporate bylaws can significantly impact shareholder value and company operations.
Key Players & Entities
- Protalix BioTherapeutics, Inc. (company) — Registrant
- December 31, 2024 (date) — Date of Report
- December 27, 2024 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of Incorporation
FAQ
What specific material modifications were made to the rights of security holders?
The filing indicates material modifications to the rights of security holders, but the specific details of these modifications are not provided in the summary text.
Were there any amendments to Protalix BioTherapeutics' articles of incorporation or bylaws?
Yes, the filing explicitly states 'Amendments to Articles of Incorporation or Bylaws' as an item information.
What is the significance of the 'Financial Statements and Exhibits' being included in this 8-K?
The inclusion of financial statements and exhibits suggests that these documents are relevant to the reported events, such as material modifications or amendments.
When was Protalix BioTherapeutics incorporated, and in which state?
Protalix BioTherapeutics, Inc. was incorporated in Delaware.
What is the SEC file number and Central Index Key for Protalix BioTherapeutics?
The SEC file number is 001-33357 and the Central Index Key is 0001006281.
Filing Stats: 830 words · 3 min read · ~3 pages · Grade level 14.3 · Accepted 2024-12-31 16:30:27
Key Financial Figures
- $0.001 — ange on which registered Common stock, $0.001 par value PLX NYSE American Indic
Filing Documents
- plx-20241227x8k.htm (8-K) — 42KB
- plx-20241227xex3d1.htm (EX-3.1) — 166KB
- 0001558370-24-016505.txt ( ) — 365KB
- plx-20241227.xsd (EX-101.SCH) — 4KB
- plx-20241227_lab.xml (EX-101.LAB) — 16KB
- plx-20241227_pre.xml (EX-101.PRE) — 11KB
- plx-20241227x8k_htm.xml (XML) — 5KB
03
Item 3.03 Material Modification to Rights of Security Holders The information set forth in Item 5.03 below is incorporated by reference into this Item 3.03.
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On December 27, 2024, the Board of Directors of Protalix BioTherapeutics, Inc., a Delaware corporation (the "Company"), unanimously approved and adopted an amendment and restatement of the Bylaws of the Company, effective immediately (the "Amended Bylaws") to, among other things: (i) amend the criteria relating to stockholders' ability to call special meetings including (a) increasing the requisite aggregate beneficial ownership of the requesting stockholders from no less than 10% to no less than 25% of all of the votes entitled to be cast on any issue proposed to be considered at the special meeting, (b) modifying the time in which the Company's secretary will fix the date of such special meeting from not less than 10 days to not less than 30 days after the receipt of such stockholder request, (c) modifying the time in which the stockholders making such request can set the special meeting date from seven days to 10 days following the receipt of such request if the Company's secretary should neglect or refuse to call such meeting, and (d) enhancing certain procedural and disclosure requirements for calling a special meeting; (ii) enhance the procedural mechanics and disclosure requirements for stockholders to make business proposals at stockholder meetings under the Company's "advance notice" or director nominations under the Company's "proxy access" bylaw provisions; (iii) addresss matters relating to the adoption of the universal proxy rules under Rule 14a-9 of the Securities Exchange Act of 1934, as amended; (iv) remove the provision that allows stockholders to act by written consent in lieu of a meeting; and (v) add that (a) the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) is the exclusive forum for litigation against the Company rel
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibit No. Description 3.1 Amended and Restated Bylaws of Protalix BioTherapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 31, 2024 PROTALIX BIOTHERAPEUTICS, INC. By: /s/ Dror Bashan Name: Dror Bashan Title: President and Chief Executive Officer